☆ 4.7 Meeting Abstract

Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).

JOURNAL OF CLINICAL ONCOLOGY (2016)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 34, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2016.34.15_suppl.TPS8570

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).

Journal

JOURNAL OF CLINICAL ONCOLOGY

Publisher

AMER SOC CLINICAL ONCOLOGY

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper